A5085228685- Atrial Fibrillation Management and Outcomes
- Renal cell carcinoma treatment
- Renal and related cancers
- Drug-Induced Hepatotoxicity and Protection
- Cardiac tumors and thrombi
- Pregnancy and Medication Impact
- Cancer Treatment and Pharmacology
- Patient Safety and Medication Errors
- Chronic Lymphocytic Leukemia Research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Treatment and Management
- Venous Thromboembolism Diagnosis and Management
- Maternal Mental Health During Pregnancy and Postpartum
- Pharmacovigilance and Adverse Drug Reactions
- Cardiovascular Issues in Pregnancy
- Pancreatic and Hepatic Oncology Research
- Cardiac electrophysiology and arrhythmias
- Opioid Use Disorder Treatment
- Neurological disorders and treatments
- Anesthesia and Sedative Agents
- Parkinson's Disease Mechanisms and Treatments
- Musculoskeletal pain and rehabilitation
- Alcoholism and Thiamine Deficiency
- Cancer Genomics and Diagnostics
- Pain Management and Opioid Use
Aarhus University Hospital
2015-2025
Aarhus University
2015-2025
Vejle Sygehus
2023
Lillebaelt Hospital
2023
ABSTRACT Chlordiazepoxide is effective in treating alcohol withdrawal syndrome, but it poses a risk of long‐term sedation. The prevalence this side effect and its factors remain uncertain. This retrospective cross‐sectional study aimed to estimate both using data from Aarhus University Hospital's BI portal. We identified manually reviewed patient records 1 September 2019 31 August 2021, including the physicians' conclusions on ICU admissions determine whether they were likely due...
Abstract Reporting of adverse incidents is mandatory in Denmark. All reported are made anonymously, and stored an encrypted database. It the purpose this descriptive study to describe severity medication caused by oral anticoagulants hospitals. moderate, severe fatal reports concerning non‐vitamin K antagonist were analyzed from date marketing until July 8 2014. The data collection for warfarin was January 1 2014 Three independent specialists clinical pharmacology evaluated incident...
Semaglutide, a GLP1 agonist, is used for glycemic control in Type 2 diabetes and weight management [1]. In animals (mice, rats rabbits), agonists associated with embryofetal mortality, structural abnormalities growth disturbances concerning delayed ossification skeletal variants [2]. A recent cohort study on the potential risk of malformations included GLP-1 receptor but did not provide specific estimates semaglutide [3]. Except case reports, there are no studies other pregnancy outcomes [1,...
Background: Metastatic renal cell carcinoma (mRCC) is notably resistant to chemotherapy and radiotherapy. However, tyrosine kinase inhibitors (TKIs) checkpoint immunotherapy have significantly improved outcomes. Still, about 20% of patients experience disease progression as their best response TKIs, 16–63% endure severe toxicities, reducing quality life. Optimizing dosing therefore essential. Therapeutic drug monitoring (TDM) a promising strategy for individualizing treatment. The TKI-TDM...
BackgroundPazopanib can induce liver toxicity in patients with metastatic renal cell carcinoma (mRCC). We assessed the effect of a TA repeat polymorphism UGT1A1 (uridine diphosphate glucuronosyltransferase 1A1) gene encoding uridine 1A1 on toxicity, dose reductions, and patient outcomes.Patients MethodsPatients mRCC treated first-line pazopanib developing underwent genotyping for polymorphism. Liver was using Common Terminology Criteria Adverse Events, version 4.0. Progression-free survival...
Introduction : Inter-individual variability in drug response pose significant challenges to treatment with tyrosine kinase inhibitors (TKI) patients metastatic renal cell carcinoma (mRCC). TKIs meet traditional criteria for using therapeutic monitoring (TDM), but research is still limited. Understanding the role of TDM individualizing strategies could help optimize treatment. Here we review state knowledge mRCC Methods A comprehensive literature original studies focusing on treatment,...
We present a case of 64-year-old man with Crohn's disease who developed parkinsonism after starting treatment infliximab (Remicade). The patient had 30-year history previous surgical procedures and methotrexate. Treatment was augmented infliximab, 3 days the first dose 400 mg, resting tremor began in left leg. Over 4 months, symptoms progressed now involved right leg as well both hands. There no clinical effect treatment, withdrawn months later. then experienced gradual, but continual,...
This study explored the question: what are doctors' perspectives on and experiences with their earlier mandatory postgraduate communication skills training?The used a qualitative, exploratory design. We purposeful sampling based principle of maximal variation to ensure different clinical perspectives. Thus, three focus groups were formed 12 doctors who had attended training within 1-9 years prior study. The from specialties: internal medicine, oncology, general practice. semi-structured...